



Esperovax, Inc.

RAPID TO MANUFACTURE, SAFE AND INEXPENSIVE
ORAL VACCINES
<http://esperovax.com>

SEPTEMBER 2020

SBDC ASSISTANCE

TECHTEAM CONSULTING

- Commercialization Strategy
- Operational Strategy
- Deal Room Preparations
- Pitch and Investor Coaching
- FDA Regulatory Compliance Topics
- Business Management and Operations Discussions
- IP Diligence Sessions
- Business and Product Roadmapping
- Competition/Market Research
- BAF Submission Preparation

BUSINESS ACCELERATOR FUND

- \$50,000 Through Ann Arbor SPARK
- Contract Research For Production Of A Key COVID-19 Vaccine Product Prototype For Starting Material/Seed Stock

ADDITIONAL SUPPORT FROM

- Ann Arbor Spark
- MichBio
- CEPI
- BARDA

President/Co-Founder David O'Hagan PhD, Chief Science Officer/Co-Founder Savita Nikam and PhD & Co-Founder Roger Newton PhD began Esperovax in 2018 to create a platform for the development of rapid to manufacture, safe and inexpensive vaccines. Esperovax has developed a proprietary EgressRD™ method of bioengineering probiotic yeast to deliver continuous and high concentrations of vaccine antigen in the small intestine. These antigens are delivered in the form of enveloped virus like particles (eVLPs) right to the lymphoid tissue of gut mucosa, inducing immune protection.

KEY ACCOMPLISHMENTS

- Demonstrated virus-like particle production and immune response stimulation in mice
- Secured \$ 1M private funding from founders, individual investors, Northern Michigan Angels, and members of the Ann Arbor and Point Angels
- Original Founder Investment \$500K
- Secured \$607,000 BARDA contract.
- On-boarded an impressive host of advisors with experience in the development of technologies for conferring viral immunity, initiating animal testing, manufacturing, testing as well as production/distribution



"SBDC has played a fundamental role in the growth and development of our company. Technology Team Member, Lindsay Klee, in particular, has been a valuable business and life sciences expert to help guide our investor dialogues and fundraising, regulatory, operational and management strategies. "

David O'Hagan, PhD, CEO

<https://sbdcmichigan.org/tech-business/>